ReviewFrontiers in bioengineering and biotechnology2026
Antibody-drug conjugates in colorectal cancer: advances in targeted delivery and personalized oncology.
Review in Frontiers in bioengineering and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer remains among the most prevalent gastrointestinal malignancies worldwide, imposing a substantial clinical burden and highlighting the urgent need for precision and personalized treatment strategies. Conventional drug delivery approaches are limited by low selectivity, restricted bioavailability, and systemic toxicity, thereby limiting therapeutic efficacy. Antibody-drug conjugates, as advanced delivery plat-forms, have the advantages of highly specific antibody recognition, versatile cytotoxic payloads, and continuously evolving linker technologies. This combination provides novel opportunities to increase efficacy, reduce toxicity, and enable individualized precision therapy. Recent advances have demonstrated the potential of ADCs in CRC, yet challenges such as resistance, toxicity, and clinical translation persist. Multidisciplinary efforts among the pharmaceutical industry and molecular biology and clinical medicine fields will be essential to accelerate the development of more precise and personalized CRC therapies. This review summarizes the current research progress on ADCs as a treatment option for CRC, discusses innovations in delivery system design, examines the key challenges of personalization, and highlights future directions to better integrate ADCs into effective treatment paradigms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.